| 20th week of 2011 patent applcation highlights part 47 |
| Patent application number | Title | Published |
|---|
| 20110118119 | SYNERGISTIC PRE-EMERGENT AND POST-EMERGENT WEED CONTROL COMPOSITIONS AND METHODS OF USE THEREOF - Methods and compositions for synergistic pre-emergent and post-emergent weed control are disclosed. In particular, the present disclosure relates to an herbicidal composition comprising at least one pre-emergent herbicide and at least one post-emergent herbicide, wherein the pre-emergent herbicide and the post-emergent herbicide synergistically inhibit pre-emergent and post-emergent development of a weed. The disclosure further relates to herbicidal compositions comprising isoxaben, 2,4-D, mecoprop-P, and dicamba. | 2011-05-19 |
| 20110118120 | SYNERGISTIC HERBICIDAL COMPOSITION CONTAINING AMINOPYRALID AND SULFONYLUREAS - An herbicidal composition containing (a) aminopyralid and (b) a sulfonylurea herbicide provides synergistic control of selected broadleaf weeds. | 2011-05-19 |
| 20110118121 | NOVEL SOLVENTS FOR 2,4-D ACID AND ACID PLANT GROWTH REGULATORS - The invention relates to a method of solubilizing a plant growth regulating agent, and method comprising contacting said agricultural active with a solubilizing effective amount of at least one solubilizing agent, wherein said solubilizing agent comprises at least one alkyl quaternary ammonium surfactant, or at least one alkoxylated quaternary ammonium surfactant, or a mixture thereof. Plant growth regulating formulations are also claimed. | 2011-05-19 |
| 20110118122 | Insecticidal pyridine compounds - The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. Novel pyridine compounds for use in controlling pests are disclosed. | 2011-05-19 |
| 20110118123 | SUPER-CONDUCTIVE NANOPARTICLE, SUPER-CONDUCTIVE NANOPARTICLE POWDER, AND LITHIUM BATTERY COMPRISING THE POWDER - A super-conductive nanoparticle, a super-conductive nanoparticle powder, and a lithium battery including the super-conductive nanoparticle powder. | 2011-05-19 |
| 20110118124 | METHOD FOR IMPROVING THE PROPERTIES OF A DRUG LEAD COMPOUND - The present patent application introduces methods for generating mixture compound libraries from a drug lead. The mixture compound libraries are then screened for the discovery of modified drug lead compounds which possess desired improved drug properties. The process utilizes a non-selective reaction to modify the drug lead compound structure. Compared to existing methods of modifying a drug lead compound, this new method can modify more structural positions of a drug lead compound. As a consequence, there will be greater probability of finding a product with improved drug properties. | 2011-05-19 |
| 20110118125 | NEONATAL SALIVARY GENOMICS - The present invention provides systems for assessing neonatal development and/or conditions by analyzing neonatal saliva RNA. Methods of identifying genes involved in neonatal development and/or conditions affecting neonates, are provided. Methods of determining a diagnosis of a neonate comprising detection of one or more differentially expressed genes are also provided. | 2011-05-19 |
| 20110118126 | METHODS OF CHEMOTYPE EVOLUTION - Herein is described a method to rapidly screen a large chemical space for a compound that binds to a target protein through an iterative fragment assembly approach that can be performed at low reagent cost and without requiring purification of the assembled product. The method employs a library of test ligands each of which comprise a ‘bait’ molecule, which is known from prior art or prior screening to have some intrinsic affinity for the target protein, and a test moiety. | 2011-05-19 |
| 20110118127 | MARKER GENES FOR SCREENING OF DRUG-INDUCED TOXICITY IN HUMAN CELLS AND SCREENING METHOD USING THE SAME - The present invention relates to a marker gene for screening a drug inducing toxicity in human and a screening method using the same. More precisely, the invention relates to a microarray on which marker genes up-or down-regulated specifically by 16 drugs inducing pulmonary toxicity, teratogenicity, nephrotoxicity, cardiotoxicity or mutation (Methotrexate, Nitrofurantoin, Amiodarone, Carbamazepine, Valproic acid, Thalidomide, Cisplatin, Gentamycin, Amphotericine, Furylfuramide, N-nitroso-N-methylurea, methylmethanesulfonate, 4-nitroquinoline-N-oxide, 2-nitrofluorene, Doxorubicin and Daunorubicin) are integrated, a kit comprising the said microarray, and a screening method of a drug inducing toxicity in human using the same. The DNA microarray containing the marker gene of the present invention facilitates the construction of Toxtarget Array for screening a drug inducing toxicity in human using drug-specific genes, suggesting that this chip can be effectively used for monitoring drugs or chemicals carrying toxicity to human or determining risks thereof and also it can be used as a tool for examining mechanisms of toxicity/side effects caused by the drugs. | 2011-05-19 |
| 20110118128 | BIOSENSOR DEVICE AND METHOD OF MANUFACTURING THE SAME - A biosensor device ( | 2011-05-19 |
| 20110118129 | METHOD FOR PREDICTING THERAPY RESPONSIVENESS IN BASAL LIKE TUMORS - The present invention is related to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of at least one gene of interest, said gene being correlated with the Estrogen receptor (ESR) status in the said sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c). Moreover, the invention concerns nucleic acid molecules usefuls as primers and probes for detecting the expression of Her2-neu/ErbB2, MLHP and MMP7, respectively. | 2011-05-19 |
| 20110118130 | Compositions and methods for defining cells - Disclosed are compositions and methods for classifying stem cells. The disclosure provides a way to define cells using a computational analysis. | 2011-05-19 |
| 20110118131 | METHODS AND MATERIALS FOR TARGETED MUTAGENESIS - The present disclosure relates to methods and materials for mutagenesis, including for the generation of novel or improved proteins and libraries or arrays of mutant proteins or nucleic acids encoding such mutant proteins. | 2011-05-19 |
| 20110118132 | Enzymatic Assays Using Umbelliferone Substrates with Cyclodextrins in Droplets of Oil - The invention is directed to droplet actuator devices and assay methods. The method may include, among other things, a method of conducting enzymatic assays using umbelliferone substrates with cyclodextrins in droplets in oil, the method including incubating a droplet in oil, the droplet preferably comprising an umbelliferone substrate, a sample, and a cyclodextrin compound. The methods may further include a method of substantially eliminating cross-contamination between droplets in enzymatic containing substrate-based bioassays. The method may include immobilization of the enzymatic substrate including forming an inclusion complex with the substrate for stabilizing the substrate within an aqueous environment, wherein the inclusion complex may be formed using cyclodextrins. In yet another embodiment, the invention may provide a method of enhancing hydrolysis of enzymatic substrates. The methods may further include a method of forming an inclusion complex with the substrate for stabilizing the substrate within an aqueous environment, wherein the substrate may be a 4-MU- or HMU containing substrate. The inclusion complex may be formed using cyclodextrin. | 2011-05-19 |
| 20110118133 | METHODS TO IDENTIFY PATIENTS AT RISK OF DEVELOPING ADVERSE EVENTS DURING TREATMENT WITH ANTIDEPRESSANT MEDICATION - The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof. | 2011-05-19 |
| 20110118134 | Biomarkers for insulin sensitizer drug response - The invention provides compositions and methods for determining insulin sensitizer drug response in a subject. The invention also provides compositions and methods for treating a subject according to insulin sensitizer drug response. | 2011-05-19 |
| 20110118135 | Mutations in Contaction Associated Protein 2 (CNTNAP2) are Associated with Increased Risk for Ideopathic Autism - The present invention provides compositions and methods for the examination of cells, tissues, and fluids, collectively known as body samples, to identify human subjects at-risk of developing Autism Spectrum Disorder by detecting a chromosomal abnormality or variant in the CNTNAP2 gene, the AUTS2 gene, or both. | 2011-05-19 |
| 20110118136 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions - Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Each compound has the formula: | 2011-05-19 |
| 20110118137 | USE OF MASS LABELED PROBES TO DETECT TARGET NUCLEIC ACIDS USING MASS SPECTROMETRY - The invention relates to the use of mass labeled probes to characterise nucleic acids by mass spectrometry. Thus the invention provides methods of detecting the presence of a target nucleic acid in a sample, using a circularising probe in which a mass tag is present in the probe. Further methods of detecting the presence of a target nucleic acid are provided, which in contrast use a probe detection sequence in the circularising probe, wherein the probe detection sequence is detected with a probe attached to a mass tag. Methods for determining a genetic profile from the genome of an organism also form part of the invention. | 2011-05-19 |
| 20110118138 | SOLID PHASE MULTI-ANALYTE ASSAY - Compositions and methods for detecting the presence and/or amount of one or more analytes, including analytes such as drugs of abuse, are provided. The compositions include two or more analytes associated with a solid phase, e.g., a particle or a multiwell plate. The compositions and methods also allow the simultaneous, tandem, or serial determination of the presence and/or amount of two or more analytes of interest in a sample. | 2011-05-19 |
| 20110118139 | Manipulation of Microparticles In Microfluidic Systems - An array of transportable particle sets is used in a microfluidic device for performing chemical reactions in the microfluidic device. The microfluidic device comprises a main channel and intersecting side channels, the main channel and side channels forming a plurality of intersections. The array of particle sets is disposed in the main channel, and the side channels are coupled to reagents. As the particle sets are transported through the intersections of the main channel and the side channels, reagents are flowed through the side channels into contact with each array member (or selected array members), thereby providing a plurality of chemical reactions in the microfluidic system. | 2011-05-19 |
| 20110118140 | METHODS FOR IDENTIFICATION, AND COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES - The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inhibiting extra-cellular matrix degradation, including joint degenerative inhibiting and/or anti-inflammatory pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving extra-cellular matrix degradation in a subject. | 2011-05-19 |
| 20110118141 | Disease Specific Diagnostic Aid - A disease specific panel having at least one primary test for different analytes that are relevant for either early detection of a primary disease or management of patients already diagnosed with said primary disease. The panel also includes at least one secondary test which is relevant for detection of a co-morbid condition or complications of the primary disease. Generally, the primary and secondary tests are disposed on a support surface. The disease specific panel is different from the prior art creening tests in that there are no tests included in the panel whose results are not relevant or do not relate to either primary disease or a co-morbid condition or complications of the primary disease. The disease specific panel may also include systems and methods utilizing algorithms for creating and outputting diagnostic aids, as well as warnings about the presence of possible sample interferants, especially those commonly associated with the subject disease of the panel. | 2011-05-19 |
| 20110118142 | DUAL LABELING METHODS FOR MEASURING CELLULAR PROLIFERATION - The present invention provides a method for measuring cellular nascent nucleic acid synthesis by dual pulse labeling of nucleic acid. The first pulse labeling of nucleic acid with a nucleoside analog allows establishment of a baseline nucleic acid synthesis rate. Pulse labeling of the nucleic acid with a second nucleoside analog then allows measurement of any changes to nucleic acid synthesis. The nucleic acid synthesis can be measured as cell proliferation, DNA, or gene expression, RNA. This method does not require a potentially artifact-inducing intermediary wash step between pulse labels. Additionally, this method may be used to screen compounds for their affect on cellular proliferation by treating cells or an organism with the test compound simultaneous to or before treatment with a competitive nucleoside analog. | 2011-05-19 |
| 20110118143 | THREE DIMENSIONAL TISSUES FOR HIGH-THROUGHPUT ASSAYS - Provided herein are methods of detecting responses of bio-artificial tissues to agents by performing assays using three-dimensional bio-artificial tissues. The methods are adaptable to high-throughput platforms. | 2011-05-19 |
| 20110118144 | ENGINEERED PHAGE VECTORS FOR THE DESIGN AND THE GENERATION OF A HUMAN NON-ANTIBODY PEPTIDE OR PROTEIN PHAGE LIBRARY VIA FUSION TO PIX OF M13 PHAGE - The invention relates to a compositions and methods for generating and using pIX phage display libraries for producing non-antibody peptide or protein proteins or peptides using engineered hybrid phage vectors derived from pIX of M 13 phage. | 2011-05-19 |
| 20110118145 | COPY NUMBER ANALYSIS OF GENETIC LOCUS - Systems and methods for analyzing copy number of a target locus, detecting a disease associated with abnormal copy number of a target gene or a carrier thereof. | 2011-05-19 |
| 20110118146 | Phage Display Using Cotranslational Translocation of Fusion Polypeptides - The present invention relates to a filamentous phage display method wherein the polypeptides of interest displayed on the phage particle are cotranslationally translocated across the cytoplasmic membrane of Gram-negative bacteria based on the signal recognition particle pathway. This method is particularly suitable for polypeptides, which are known to be difficult to display on phages, and for proteins of cDNA libraries and other combinatorial libraries, in particular when derived from very fast folding, stable protein scaffolds. The invention further relates to phage or phagemid vectors useful in the method comprising a gene construct coding for a fusion polypeptide comprising the polypeptide to be displayed on the phage particle and an N-terminal signal sequence promoting cotranslational translocation. | 2011-05-19 |
| 20110118147 | LIBRARIES OF GENETIC PACKAGES COMPRISING NOVEL HC CDR3 DESIGNS - Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library. | 2011-05-19 |
| 20110118148 | NUCLEAR MAGNETIC RESONANCE ASSEMBLY OF CHEMICAL ENTITIES USING ADVANCED ANTENNA PROBES - The invention provides a method for identifying a ligand that binds to a macromolecular target. The methods involve (a) attaching an antenna moiety to a first ligand, wherein the ligand binds specifically to a macromolecular target; (b) providing a sample comprising the macromolecular target, the first ligand and a candidate second ligand under conditions wherein the first ligand and the macromolecular target form a bound complex; (c) detecting a subset of magnetization transfer signals between the antenna moiety of the first ligand and the second candidate ligand, wherein the signals are obtained from an isotope edited NOESY spectrum of the sample; thereby determining that the two ligands are proximal in a bound complex, and identifying a second ligand that binds to the macromolecular target. | 2011-05-19 |
| 20110118149 | Synthetic Polypeptide Libraries and Methods for Generating Naturally Diversified Polypeptide Variants - The invention provides compositions and methods for generating libraries of DNA sequences encoding homologous polypeptides, and uses of the libraries to identify naturally diversified polypeptide variants. The invention also provides compositions and methods for generating collections of synthetic antibody fragments in which one or several complementary determining regions (CDR) are replaced by a collection of the corresponding CDR captured from a natural source. The invention further provides compositions and methods for diversifying a portion of a polypeptide by inserting a diversified sequence of synthetic or natural origin without the need for modification of the original polypeptide coding sequence. | 2011-05-19 |
| 20110118150 | METHOD FOR MAKING BIOCHIPS - A method for immobilizing biological polymers such as DNA or proteins, on a solid support, by ionocovalent bond, for making biochips, and the resulting chips obtained by the method. Also, a kit for the preparation of the chips. | 2011-05-19 |
| 20110118151 | MULTIPLE DISPLACEMENT AMPLIFICATION - The present invention provides methods kits and systems for performing multiple displacement amplification reactions. In one method a sample of nucleic acid is provided. The nucleic acid is contacted with a reaction mixture which includes a set of oligonucleotide primers, a one or more polymerase enzymes and a detergent. The reaction mixture is then subjected to conditions under which the nucleic acid sequence is amplified to produce an amplified product in a multiple displacement reaction. The method may also be carried out by contacting the nucleic acid with the reaction mixture in the form of an emulsion. A kit is also provided for carrying out either the methods described above. The kit includes one or more polymerases, a plurality of primers and a detergent. The kit may also include a hydrophobic polymer and may include instructions for performing a multiple displacement amplification reaction on a nucleic acid sample. | 2011-05-19 |
| 20110118152 | NOVEL METHOD FOR THE TREATMENT OF ROCK FORMATIONS AND NOVEL POLYAMPHOLYTES - A method for the treatment of rock formations which may or may not be underground and, more particularly, of oil or gas production wells, water-injection wells intended to flood hydrocarbon (oil or gas) reservoirs or gas mines or gas storage wells includes a step of injecting, into the rock formation or well, a microgel obtained by dilution in water of a self-invertible inverse latex or of a self-invertible inverse microlatex of a crosslinked polyelectrolyte, obtained by copolymerization, in the presence of a crosslinking agent of partially- or totally-salified free 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid, with at least one cationic monomer chosen from: 2,N,N,N-tetramethyl-2-[(1-oxo-2-propenyl)amino]propanammonium chloride; N,N,N-trimethyl-3-[(1-oxo-2-propenyl)amino]propanammonium chloride; diallyldimethylammonium chloride; N,N,N-trimethyl-2-[(1-oxo-2-propenyl)]ethanammonium chloride; N,N,N-trimethyl-2-[(1-oxo-2-methyl-2-propenyl)]ethanammonium chloride; or N,N,N-trimethyl-3-[(1-oxo-2-methyl-2-propenyl)amino]propanammonium chloride; and with at least one neutral monomer chosen from: acrylamide; N,N-dimethylacrylamide; N-[2-hydroxy-1,1-bis(hydroxymethyl)-ethyl]propenamide; or 2-hydroxyethyl acrylate. | 2011-05-19 |
| 20110118153 | METHOD OF CONTINUOUS DISSOLUTION OF POLYACRYLAMIDE EMULSIONS FOR ENHANCED OIL RECOVERY (EOR) - Enhanced oil recovery method consisting in continuously dissolving, in the injection water, a stable invert emulsion of acrylamide (co)polymer containing at least one inverting agent, and a water soluble polymer, whereby:
| 2011-05-19 |
| 20110118154 | METHOD OF MAKING A SYNTHETIC ALKYLARYL SULFONATE - A process for preparing an alkylaryl sulfonate comprising (a) reacting at least one meta-xylene compound with olefin or a mixture of olefins having from about 10 to about 20 carbon atoms, in the presence of an acid catalyst, wherein the resulting product comprises no more than 40 weight percent of 1-alkyl-2,4 dimethylsubstituted aromatic compound and at least about 60 weight percent of 1-alkyl-3,5 dimethyl substituted aromatic compound; (b) sulfonating the product of (a); and (c) neutralizing the product of (b) with a source of alkali or alkaline earth metal or ammonia. | 2011-05-19 |
| 20110118155 | LIGHT-WEIGHT PROPPANT FROM HEAT-TREATED PUMICE - A process for forming a strong, low-density proppant, which process includes heating pumice particulates, or shaped agglomerates thereof, so as to form heat-treated pumice particulates, or heat-treated, shaped pumice agglomerates, having an apparent density of 2.4 or less and a crush resistance of no more than 10% fines at 4000 psi. Proppants, and well treatment fluids comprising proppants, meeting these characteristics and processes for treating subterranean formations using fluids which include such proppants are also described. | 2011-05-19 |
| 20110118156 | LUBRICANT ADDITIVES FOR IMPROVING THE TRIBOLOGICAL PROPERTIES, NOVEL LUBRICANTS, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF - The present invention relates to novel lubricant additives for improving the tribological properties, novel lubricants containing these additives, processes for the preparation thereof and the use thereof. | 2011-05-19 |
| 20110118157 | RUST INHIBITORS TO MINIMIZE TURBO SLUDGE - A turbo-charged, sump-lubricated internal combustion engine which is susceptible to contamination of lubricant with liquid fuel, may be lubricated with a lubricant which contains an amount of a rust inhibitor effective to reduce the deterioration of said lubricant and turbo sludge formation. | 2011-05-19 |
| 20110118158 | LUBRICATING OIL COMPOSITION FOR ROLLING WITH ROUND DIE - Provided is a lubricating oil composition for round die rolling, which is obtained by blending a base oil with: (A) 0.5 to 40 mass % of a monoester having 13 to 48 carbon atoms (a-1) and/or 0.5 to 30 mass % of a fatty dicarboxylate having 13 to 34 carbon atoms (a-2); (B) 0.01 to 10 mass % of a thiadiazole compound; (C) 0.01 to 15 mass % of a thiophosphite; and (D) 0.01 to 5 mass % of a triazole compound. The lubricating oil composition for round die rolling shows excellent processing performance without using any chlorine-based compound, and is able to improve lubricity in a bearing to lengthen the life of the bearing. | 2011-05-19 |
| 20110118159 | FUEL OIL COMPOSITIONS WITH IMPROVED COLD FLOW PROPERTIES - The use is described of polymers which contain, in copolymerized form, an α-olefin, a vinyl ester and an ester of an α,β-unsaturated carboxylic acid as an additive for fuel oils and lubricants and in particular as a cold flow improver in fuel oils. In addition, the fuel oils and lubricants additized with these polymers; and also additive packages comprising such polymers are described. | 2011-05-19 |
| 20110118160 | Alkylated hydroxyaromatic compound substantially free of endocrine disruptive chemicals - An alkylated hydroxyaromatic compound is disclosed which is prepared by reacting at least one hydroxyaromatic compound with at least one branched olefinic propylene oligomer having from about 20 to about 80 carbon atoms in the presence of an acid catalyst, wherein the at least one branched olefinic propylene oligomer is substantially free of any vinylidene content. The alkylated hydroxyaromatic compound has been determined to be substantially free of endocrine disruptive chemicals when the effects were quantified on pubertal development and thyroid function in the intact juvenile female rat. | 2011-05-19 |
| 20110118161 | CAPSULE WITH ORGANIC/INORGANIC HYBRID WALL - The present invention relates to a capsule, comprising or consisting of a core and a shell surrounding the core, wherein the shell comprises a polymeric material or consists thereof, which polymeric material can be produced by reacting a component (A) with a component (B), wherein
| 2011-05-19 |
| 20110118162 | LIQUID PERSONAL CLEANSING COMPOSITION - A mild, substantially isotropic skin cleansing solution was found to be able to suspend insoluble components and provide copious amounts of lather. The cleanser is formulated with synthetic anionic surfactants and a specific ratio of carboxylic acid(s) to hydrophobically modified cross-linked acrylate copolymer(s). The carboxylic acid and acrylate polymer combination were found to provide a synergistic effect on zero shear viscosity at 25 C in a specific pH and copolymer/acid concentration ratio range. | 2011-05-19 |
| 20110118163 | FRAGRANCE DELIVERY SYSTEM - A fragrance delivery system comprises a suspension concentrate including a suspending matrix and a fragrance material which system can be diluted with water to form a use composition such as a body wash formulation. | 2011-05-19 |
| 20110118164 | Foamable Skin Washing Agent - To provide a skin washing agent which is excellent in the foaming speed and the foam creaminess in washing therewith, and which, after washing therewith, is excellent in the moist feeling and the absence of pulling feeling of the skin and does not change the moisture content of skin. A foamable skin washing agent comprising (a) a fatty acid salt, (b) one or more selected from a homopolymer, a dipolymer and a terpolymer derived from a specific cationated monomer (e.g., dimethyldiallylammonium chloride), (c) a polyglyceryl monoalkyl ether, and (d) one or more selected from an acylmethyltaurine salt and a hydroxy ether carboxylate salt. | 2011-05-19 |
| 20110118165 | COMPOSITION AND METHOD FOR TREATING SEMICONDUCTOR SUBSTRATE SURFACE - The present invention is directed to compositions and method of use for treating semiconductor substrate comprising a sulfonium compound and a nucleophilic amine in the fabrication of electronic devices. Optionally, the said composition further comprises a chelating agent, and solvent. The pH of the said solution can be adjusted with the addition of acid or base. The semiconductor manufacturing processes include steps for post etch residue, photoresist removal and steps during chemical mechanical planarization and post chemical mechanical planarization. | 2011-05-19 |
| 20110118166 | SOLIDIFICATION MATRIX - A cleaning composition includes methacrylate, sodium carbonate, and water. The methacrylate, sodium carbonate, and water interact to form a hydrate solid having a growth exponent of less than about 3% when heated. The composition may also include one or more functional ingredients such as surfactants, builders and alkaline sources, but is generally substantially free of phosphorous. | 2011-05-19 |
| 20110118167 | Composition for Protection of Glassware in Dishwasher - The present invention provides a composition. The composition comprises zinc and bismuth. The composition is for use in the protection of glassware in an automatic dishwashing process from detrimental effects caused by exposure to aluminium. | 2011-05-19 |
| 20110118168 | Cleaning Composition Comprising Graft Copolymers - Disclosed is the use of water-soluble graft copolymers prepared by free-radically initiated graft polymerization of 40 to 90% by weight of component (A), selected from the group consisting of monosaccharides, oligosaccaharides, polysaccharides and derivatives thereof, with 5 to 40% by weight of monomers (B), selected from the group consisting of ethylenically unsaturated C3-C10 monocarboxylic acids or the alkali or ammonium salts thereof, and 10 to 50% by weight of monomers (C), selected from the group consisting of ethylenically unsaturated N-containing monomers and/or ethylenically unsaturated monomers containing sulfo-groups, in cleaning compositions which, as well as the graft polymer, comprise at least one surfactant component, for hydrophilization and/or improvement of shine retention of hard surfaces which have been brought into contact with these cleaning compositions. | 2011-05-19 |
| 20110118169 | REUSABLE ANTISTATIC DRYER PRODUCTS AND METHODS FOR FABRICATING THE SAME - Dryer products that impart antistatic properties to textiles and methods for fabricating such dryer products are provided. In one exemplary embodiment, a dryer product comprises a water-insoluble, moisture-permeable, enclosed container and a desiccant within the water-insoluble, moisture-permeable, enclosed container. The desiccant is adapted to impart antistatic properties to the textiles during a drying cycle. In another exemplary embodiment, a method for fabricating a reusable antistatic dryer product comprises the steps of providing a desiccant adapted to absorb moisture and be solubilized in the moisture, depositing the desiccant in a water-insoluble, moisture-permeable container, and enclosing the desiccant within the water-insoluble, moisture-permeable container. | 2011-05-19 |
| 20110118170 | NOVEL 4-ALKYL 1-(3-METHOXY-2-PROPEN-1-YL) BENZENE COMPOUNDS AND THEIR USE IN PERFUME COMPOSITIONS - The present invention is directed to novel 4-alkyl 1-(3-methoxy-2-propen-1-yl)benzene compounds and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of the novel compounds. | 2011-05-19 |
| 20110118171 | PROCESS FOR PRODUCING FATTY ACID AND ACTIVE INGREDIENT EXTRACTS, AND FATTY ACIDS AND ACTIVE INGREDIENTS THEMSELVES - A method for producing especially oleic acid and fatty acid extracts, and oleic acids and fatty acids themselves. In order to obtain active ingredients, especially oleic acids or fatty acids, from a noninvasive plant in large amounts, without the use of genetic manipulation processes, for reasons relating to agricultural laws, the oleic acid or fatty acid extracts are obtained from the biological material, i.e. the plant material, of the novel plant variety CANDY (CPVO 2007/1958). | 2011-05-19 |
| 20110118172 | METASTIN DERIVATIVE AND USE THEREOF - The invention provides a stable metastin derivative having excellent biological activities (a cancer metastasis-inhibiting activity, a cancer proliferation-inhibiting activity, a gonadotropin secretion-promoting activity, a sex hormone secretion-promoting activity, etc.). By replacing the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, the blood stability and solubility of the metastin derivative can be more improved, the gel tendency of the metastin derivative can be reduced, the pharmacokinetics of the metastin derivative can be improved, and the metastin derivative can exhibit an excellent cancer metastasis-inhibiting activity and cancer proliferation-inhibiting activity. The metastin derivative can also exhibit a gonadotropin secretion-inhibiting activity, a sex hormone secretion-inhibiting activity, etc. | 2011-05-19 |
| 20110118173 | METHOD OF DELIPIDATION OF HDL USING SERUM OPACITY FACTOR TO PREVENT, INHIBIT, AND/OR REVERSE ATHEROSCLEROSIS - This invention relates to delivering a therapeutically active serum opacity factor or an anti-atherosclerotic therapeutic lipoprotein generated from interaction with serum opacity factor to an individual that has or is at risk for atherosclerosis. This can be accomplished by in vivo or ex vivo delivery methods. | 2011-05-19 |
| 20110118174 | TREATMENT SOLUTION AND METHOD FOR PREVENTING POSTERIOR CAPSULAR OPACIFICATION BY SELECTIVELY INDUCING DETACHMENT AND/OR DEATH OF LENS EPITHELIAL CELLS - A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and/or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and/or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment. | 2011-05-19 |
| 20110118175 | COMPETITIVE INHIBITORS OF INVARIANT CHAIN EXPRESSION AND/OR ECTOPIC CLIP BINDING - The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products. | 2011-05-19 |
| 20110118176 | NOVEL POSSIBILITY OF CONTROLLING DISEASES CAUSED BY TRICHOMONADIDA - The present invention relates to the use of nifurtimox for the treatment of diseases caused by trichomonads, such as, for example, histomoniasis, in particular in turkeys. | 2011-05-19 |
| 20110118177 | BIOTECHNOLOGICAL PRODUCTION OF CYANOPHYCIN DIPEPTIDES - The present invention relates to a process for the enzymatic production of a dipeptide composition from a cyanophycin (CGP) or CGP-like polymer preparation by degrading the polymer preparation with an CGPase, a CGPase particularly adapted for said process, and the use of cyanophycin (CGP) or CGP-like polymers or fragments thereof, notably a dipeptide composition obtained by the process as defined above, as pharmaceutical composition, medicament, or as food or feed substitute. | 2011-05-19 |
| 20110118178 | METHOD OF TREATMENT OF DIABETES TYPE 2 COMPRISING ADD-ON THERAPY TO INSULIN GLARGINE AND METFORMIN - A method for the treatment of diabetes mellitus type 2 comprising administering
| 2011-05-19 |
| 20110118179 | CATION COMPLEXES OF INSULIN COMPOUND CONJUGATES, FORMULATIONS AND USES THEREOF - An insulin compound coupled to a modifying moiety having a formula: | 2011-05-19 |
| 20110118180 | METHOD OF TREATMENT OF DIABETES TYPE 2 COMPRISING ADD-ON THERAPY TO METFORMIN - A method for the treatment of diabetes mellitus type 2 comprising administering
| 2011-05-19 |
| 20110118181 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF - A method for identifying a compound for preventing or treating a LDLR-associated disease, a VLDLR-associated disease or an ApoER2-associated disease, said method comprising determining whether: a) a level of expression of Annexin A2 nucleic acid or encoded polypeptide; b) a level of Annexin A2 activity; or c) a combination of a) and b), is increased in the presence of a test compound relative to in the absence of said test compound, wherein said increase is indicative that said test compound can be used for preventing or treating a LDLR-associated disease, a VLDLR-associated disease, an ApoER2-associated disease. | 2011-05-19 |
| 20110118182 | PROCESS FOR THE EXTRACTION, PURIFICATION AND ENZYMATIC MODIFICATION OF SOY 7S GLOBULIN ALPHA' SUBUNIT FOR USE AS HYPOCHOLESTEROLEMIZING AGENT - A purified amino-terminal polypeptide fragment of the soy β-conglycinin α′ subunit is prepared by selective extraction of defatted soy with an aqueous solution of sodium bisulfite, precipitation with ethanol, and Metal Affinity Chromatography (MAC) under denaturing conditions to obtain the α′ subunit. The α′ subunit is then enzymatically treated with chymotrypsin and subjected to further MAC to recover the amino-terminal fragment of the polypeptide (MW 28,000 Da). | 2011-05-19 |
| 20110118183 | N-GLYCOSYLATED HUMAN GROWTH HORMONE WITH PROLONGED CIRCULATORY HALF-LIFE - The present invention relates to novel human growth hormone (hGH) variant(s) with one or more N-glycans. The hGH variants of the invention comprises an amino acid sequence which includes at least one N-glycosylation motif (N-X-S/T) arising from one or more mutations not present in the wild type hGH. The hGH variants of the invention have a prolonged circulatory half-life and thus can be effectively used as a protein therapeutic for disease states that will benefit from increased levels of hGH. The process of obtaining the hGH variants is also encompassed by the invention. | 2011-05-19 |
| 20110118184 | Treatments of Gastrointestinal Disorders - The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms. | 2011-05-19 |
| 20110118185 | AMINO ACID SEQUENCES DIRECTED AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CONDITIONS AND DISEASES CHARACTERIZED BY EXCESSIVE AND/OR PATHOLOGICAL ANGIOGENESIS OR NEOVASCULARIZATION - The present invention relates to amino acid sequences that are directed against vascular endothelial growth factor (VEGF), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization. | 2011-05-19 |
| 20110118186 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF - The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P | 2011-05-19 |
| 20110118187 | REVERSIBLE PLATELET INHIBITION - The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same. | 2011-05-19 |
| 20110118188 | FACTOR VIII POLYPEPTIDE HAVING FACTOR VIII:C ACTIVITY - Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same. | 2011-05-19 |
| 20110118189 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE - Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination. | 2011-05-19 |
| 20110118190 | Postsynaptically Targeted Chemodenervation Agents and Their Methods of Use - Improved chemodenervation agents are provided comprising polypeptide α-neurotoxins having high binding specificity and selectivity for the human muscular α1 nAChR instead of the human neuronal α7 nAChR, along with pharmaceutical compositions and methods of use. | 2011-05-19 |
| 20110118191 | Crotoxin Administration for Cancer Treatment and Pain Relief - Disclosed is a method for treating cancer and/or pain using an intra-patient dose escalation procedure to deliver dosages of crotoxin. | 2011-05-19 |
| 20110118192 | METHODS AND COMPOSITIONS FOR TREATING T-CELL LEUKEMIA - The present invention relates to compositions and methods that may be used to diagnose and treat cancer, particularly T-cell leukemia. According to one preferred embodiment of the present invention, methods are provided for determining whether reducing or blocking NOTCH-1 activation will be effective to treat, prevent, or ameliorate the effects of a cancer in a patient, including T-cell leukemia, myeloleukemia, neuroblastoma, breast cancer, and ovarian cancer. The methods generally include determining if the patient harbors one or more mutations in a PTEN coding region. In particular, the methods may be used to determine whether reducing or blocking NOTCH-1 activation, with one or more γ-secretase inhibitors, will be effective to treat, prevent, or ameliorate the effects of a cancer in a patient. | 2011-05-19 |
| 20110118193 | TREATMENT OF LIQUID CANCERS - A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used in the manufacture of a medicament for the treatment of a blood cancer in a mammal by administering the medicament in a therapeutically effective amount. | 2011-05-19 |
| 20110118194 | Therapeutic Use of LPI, a Staphylococcal Lectin Pathway Inhibitor in Inflammatory Diseases - The invention relates to nucleic acid molecules encoding (poly)peptides having LPI (Lectin Pathway Inhibitor) activity, to recombinant vectors harboring such molecules, and the host cells carrying the vectors. The invention further relates to methods for preparing recombinant (poly)peptides having LPI activity and to the use of such recombinant (poly)peptides having LPI activity for diagnosis, prophylaxis and treatment, such as the treatment of inflammation reactions. In addition the invention provides therapeutic and diagnostic compositions comprising as the active ingredient the (poly)peptide having LPI activity. | 2011-05-19 |
| 20110118195 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. | 2011-05-19 |
| 20110118196 | ANTI-PHTHIRAPTERA TREATMENT COMPOSITIONS - Liquid ovicidal/pediculicidal compositions for eradication of ectoparasites, such as head-lice and other phthiraptera, are disclosed. The compositions comprise 5-50 weight percents of a film-forming carbohydrate and optionally 1-10 weight percents of oil, and are washable within a time period of 1-5 minutes from hair at a length of less than 60 cm in a stream of water of at least 5 liters per minute and a temperature lower than 40° C. Hair care formulations such as shampoos, conditioners, mousses, gels and the likes containing such an ovicidal/pediculicidal composition are further disclosed. Also disclosed are methods preparing and using the compositions and formulations. | 2011-05-19 |
| 20110118197 | PREVENTION OF HEPATIC ISCHEMIC REPERFUSION INJURY BY ADMINISTRATION OF SULFATIDES - Hepatic ischemic reperfusion injury is a major complication of liver transplantation, resectional hepatic surgeries, trauma surgery and shock. Disclosed herein are methods for the prevention and treatment of ischemia and reperfusion injury with the administration of sulfatides. Also disclosed herein are methods of preventing and treating hepatic reperfusion injury by administering an amount of a sulfatide to the body of a patient effective to reduce or prevent the symptoms of the injury. | 2011-05-19 |
| 20110118198 | POLYSULFATED GLYCOSIDES AND SALTS THEREOF - The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies. | 2011-05-19 |
| 20110118199 | USE OF CNS PENETRATING ANTICANCER COMPOUNDS FOR THE TREATMENT OF PROTOZOAL DISEASES - The present invention relates to the treatment of protozoal diseases by administering cytotoxic and/or cytostatic compounds, in particular those used in anticancer therapy, to patients. In particular, the invention relates to the use of anticancer agents that can penetrate into the CNS for treatment of late stage African sleeping sickness or cerebral malaria. | 2011-05-19 |
| 20110118200 | A PEGYLATED AND FATTY ACID GRAFTED CHITOSAN OLIGOSACCHARIDE, SYNTHESIS METHOD AND APPLICATION FOR DRUG DELIVERY SYSTEM - The present invention provides a PEGylated and fatty acid grafted chitosan oligosaccharide comprising a structural unit represented by the following Formula (I) and a structural unit represented by the following Formula (II) and synthesize method, wherein the chitosan oligosaccharide has a molecular weight of less than 200,000 Da, and a degree of deacetylation of 70%-100%, and part of free amino groups of chitosan oligosaccharide chain are replaced by a fatty acid or PEG, where n refers to degree of polymerization of the PEG, and R is an alkyl group having 11-21 carbon atoms. The grafting ratio of fatty acids is 1%-50%, and the grafting ratio of PEG is 0.05%-50%. The present invention also comprise a pharmaceutical composition comprising the PEGylated and fatty acid grafted chitosan oligosaccharide as a carrier, and use of the PEGylated and fatty acid grafted chitosan oligosaccharide in preparation of a pharmaceutical composition. | 2011-05-19 |
| 20110118201 | GLUTATHIONE PRODUCTION ENHANCER, PROPHYLACTIC/THERAPEUTIC AGENT FOR DISEASES CAUSED BY GLUTATHIONE DEFICIENCY, AND FOOD, BEVERAGE AND FEED - The invention aims at finding a highly-safe natural product having glutathione production-enhancing activity, and providing a glutathione production enhancer and a prophylactic/therapeutic agent for diseases caused by glutathione deficiency using that natural product as an active ingredient. The glutathione production enhancer or the prophylactic/therapeutic agent for diseases caused by glutathione deficiency contains, as an active ingredient, a licorice extract composition that contains liquiritin, liquiritigenin, isoliquiritin and isoliquiritigenin but contains substantially no glycyrrhizic acid. | 2011-05-19 |
| 20110118202 | Molecules which Bind to the Dimerization Initiation Site (DIS) of HIV RNA, Their Synthesis and Their Applications as Drugs - The dimerization of HIV RNA is a key step in the virus replication cycle. Based on RNA DIS crystal structures, a novel kind of compounds, dimeric or not, based on neamine was designed and synthesized. Biological studies showed that such compounds bind and interfere with the targeted RNA sequence, opening a new anti-HIV approach. The crystal structures and bio-chemical experiments showed that the DIS of HIV-1 genomic RNA is a target for new anti-HIV drugs and that those drugs could be derived from aminoglycosides. The results revealed that binding of aminoglycosides to the DIS is specific regarding both the aminoglycoside family and the RNA subtype. | 2011-05-19 |
| 20110118203 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound - The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1Hbenzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy. | 2011-05-19 |
| 20110118204 | NUTRITIONAL COMPOSITION WITH FREE AMINO ACIDS AND STRUCTURED LIPIDS - A nutritional composition is proposed, such as an infant formula composition or an enteral composition for children 3-17 years, that is especially targeted as patients having food allergies or impairments of intestinal absorption. The composition comprises structured lipids. The composition is based on free amino acids and contains a very low amount of peptides or proteins, if any. The composition comprises a source of carbohydrate and has a particular caloric density. The composition can comprise arachidonic acid (ARA) and/or docosahexaenoic acid (DHA). The composition delivers specific nutritional benefits to the patients. | 2011-05-19 |
| 20110118205 | ANTI-TUMOR AGENT COMPRISING CYTIDINE DERIVATIVE AND CARBOPLATIN - Provision of a novel combined therapy with ECyd, which therapy exhibits remarkable antitumor effect and gives less adverse effects. | 2011-05-19 |
| 20110118206 | HYALURONIC ACID BASED FORMULATIONS - Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on low molecular weight hyaluronic acids and pharmaceutically acceptable salts thereof, and methods of manufacturing same. | 2011-05-19 |
| 20110118207 | MODIFIED HYDROXYPOLYMER CONJUGATES WITH BONE SEEKING AND TUMOR KILLING MOIETIES - The present invention is related to a modified hydroxypolymer conjugate, preferably a dextran-guanidine-biphosphonate conjugate for treating not only skeletal tumors i.e. bone metastasis, particularly bone metastasis related to hormone refractory prostate cancer HRPC and breast cancer, but also osteoporosis. A method for producing and using said hydroxypolymer conjugate is also disclosed. | 2011-05-19 |
| 20110118208 | Thiazolyl-Dihydro-Indazoles - The present invention encompasses compounds of general formula (1) | 2011-05-19 |
| 20110118209 | SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF AS ANTI-TUMOR AGENTS - The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula | 2011-05-19 |
| 20110118210 | AMINOPROPANOL DERIVATIVES - Compounds of formula I: | 2011-05-19 |
| 20110118211 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME - Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure | 2011-05-19 |
| 20110118212 | Pestcidal active mixtures comprising isoxazoline compounds I - The present invention relates to pesticidal mixtures comprising as active compounds
| 2011-05-19 |
| 20110118213 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS - This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula: | 2011-05-19 |
| 20110118214 | LIGANDS SPECIFIC FOR CANNABINOID RECEPTOR SUBTYPE 2 - A compound of Formula I: (I) has activity as a cannabinoid receptor antagonist. In Formula 1, R1 is unsubstituted or substituted aryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted heteroaryl; R2 is unsubstituted or substituted alkyl, unsubstituted or substituted aryl, or unsubstituted or substituted heteroaryl; and R3 is unsubstituted or substituted alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted heteroaralkyl; with the proviso that at least one of Ri and R3 is other than unsubstituted aralkyl or R2 is other than unsubstituted aryl. | 2011-05-19 |
| 20110118215 | 7,8 And 9-Substituted Tetracycline Compounds - 7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described. | 2011-05-19 |
| 20110118216 | Tigecycline Compositions and Methods of Preparation - The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer. | 2011-05-19 |
| 20110118217 | Agonists for Antimicrobial Peptide Systems - Short chain fatty acids (SCFAs) and glycerol esters of SCFAs not previously used for that purpose are provided for use as a medicament for treating, preventing or counteracting microbial infections in animals, including humans, by stimulating the innate antimicrobial peptide defense system. Preferred compounds include phenyl substituted short chain fatty acids (SCFAs) derivatives and. Also provided are methods and compositions for treating, preventing or counteracting microbial infections, including bacterial, viral, fungal, and parasitic infections, by administration of medicaments comprising a secretagogue-effective amount of the compounds of the invention. | 2011-05-19 |
| 20110118218 | TREATING HYPERTENSION WITH 25-HYDROXYVITAMIN D3 - We disclose the use of optionally in combination with vitamin D3 (cholecalciferol), 25-hydroxyvitamin D3 (cal-cifediol), to treat hypertension. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 2011-05-19 |
